Ubiquitin E3 ligase
US7923219B2 · kind B2 · utility
34Cited by
3References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2006 |
| Grant date | Apr 12, 2011 |
| Priority date | — |
| Expiry date | Apr 15, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides a native or reconstituted complex comprising Bmi1 and/or Ring1 and/or Ring2, wherein the complex has ubiquitin E3 ligase activity. Optionally, the complex further comprises HPH2 and/or HPC3. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that modulate the ubiquitin E3 ligase activity of the native or reconstituted complex, and methods of identifying candidate compounds for treating cancer. Kits for determining modulation of protein ubiquitination and/or for ubiquitinating a target substrate are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.